IDEXX Laboratories, Inc.
NASDAQ:IDXXMedical - Diagnostics & Research
+$12.33 today
- Market cap
- $55.03B
- Beta
- 1.54
- P/E (TTM)
- 40.8
- EPS (TTM)
- $13.67
Volume 0.37M
Average 0.58M
IDXX Total Current Liabilities
All obligations due within one year.
IDEXX Laboratories, Inc.NASDAQ: IDXX
Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total current liabilities broadly unchanged from a year ago
Total current liabilities stood at $1.26B at the end of Q3 FY2026, up 1.0% from a year earlier and down 1.8% from the prior quarter. Over 3 fiscal years it compounded at -2.4% a year.
Context
- Total current liabilities amounted to 34.1% of total assets at the end of Q3 FY2026, down 2.9 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +1.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.15B USD
- Year-over-year change
- +7.6%
- 4-year CAGR
- +10.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.15B | +7.6% |
| FY2024 | 2024-12-31 | 1.07B | +12.2% |
| FY2023 | 2023-12-31 | 951.55M | -23.0% |
| FY2022 | 2022-12-31 | 1.24B | +61.8% |
| FY2021 | 2021-12-31 | 763.58M | — |
Total Current Liabilities vs competitors
How IDXX compares with its peers on the latest reported figures
- IDXX's Sep 2026 total current liabilities of $1.26B is the 4th highest of the 5 companies compared; the peer median is $1.92B.
- Its year-over-year change of +1.0% is the 4th highest of 5, against a peer median of +4.4%.
- Total current liabilities amounts to 34.1% of total assets for IDXX, versus a peer median of 13.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $27.73B | +6.5% | +5.3% | 21.4% | |
| Jun 2026 | $2.06B | -38.8% | -11.0% | 13.7% | |
| Sep 2026 | $1.79B | +22.8% | -2.1% | 13.4% | |
| Sep 2026 | $1.26B | +1.0% | -2.4% | 34.1% | |
| Aug 2026 | $149.5M | +2.3% | +2.8% | 4.5% | |
| Peer median (excluding IDXX) | $1.92B | +4.4% | +0.4% | 13.5% | |
Competitors are the stored peer set for IDXX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 144.45M | 112.55M | 453.93M | 288.27M | 180.07M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 425.58M | 490.9M | 529.53M | 561.32M | 693.19M |
| Inventory | 269.03M | 367.82M | 380.28M | 381.88M | 377.76M |
| Other Current Assets | 74.59M | 88.46M | 83.14M | 109.81M | 31.35M |
| Total Current Assets | 955.66M | 1.1B | 1.5B | 1.4B | 1.34B |
| Property, Plant & Equipment (Net) | 692.77M | 768.09M | 817.68M | 829.25M | 870.61M |
| Goodwill | 359.35M | 361.8M | 365.96M | 405.1M | 414M |
| Intangible Assets | 99.04M | 97.67M | 84.5M | 111.68M | 109.84M |
| Long-term Investments | 18.6M | 55.5M | 56.19M | 57.72M | 297.09M |
| Tax Assets | 24.78M | 55.22M | 107.36M | 125.63M | 27.87M |
| Other Non-current Assets | 287.02M | 307.01M | 332.98M | 364.17M | 291.08M |
| Total Non-current Assets | 1.48B | 1.65B | 1.76B | 1.89B | 2.01B |
| Total Assets | 2.44B | 2.75B | 3.26B | 3.29B | 3.35B |
| Account Payables | 116.14M | 110.22M | 110.64M | 114.21M | 110.41M |
| Short-term Debt | 148.5M | 653.98M | 325M | 417.79M | 500.07M |
| Tax Payables | 42.61M | 48.55M | 86.55M | 62.25M | 0 |
| Deferred Revenue | 40.03M | 37.94M | 37.2M | 33.8M | 35.26M |
| Other Current Liabilities | 182.93M | 142.99M | 174.38M | 174.58M | 201.96M |
| Total Current Liabilities | 763.58M | 1.24B | 951.55M | 1.07B | 1.15B |
| Long-term Debt | 775.21M | 694.39M | 622.88M | 449.79M | 475.99M |
| Deferred Tax Liabilities | 8.94M | 8.15M | 7.24M | 11.31M | 31.87M |
| Deferred Revenue (Non-current) | 41.17M | 30.86M | 28.53M | 26.94M | 32.18M |
| Other Non-current Liabilities | 70.94M | 67.59M | 65.53M | 44.34M | (44.62M) |
| Total Non-current Liabilities | 983.63M | 902.23M | 823.85M | 630.21M | 596.56M |
| Total Liabilities | 1.75B | 2.14B | 1.78B | 1.7B | 1.75B |
| Common Stock | 10.69M | 10.72M | 10.75M | 10.78M | 10.84M |
| Retained Earnings | 2.92B | 3.6B | 4.44B | 5.33B | 6.39B |
| Accumulated OCI | (53.48M) | (77.8M) | (71.21M) | (93.65M) | (68.84M) |
| Other Stockholders Equity | 5.72M | 5.18M | 5.53M | 5.89M | 6.09M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 689.99M | 608.74M | 1.48B | 1.6B | 1.61B |
| Total Debt | 1.03B | 1.47B | 1.07B | 986.95M | 1.08B |
| Net Debt | 886.56M | 1.36B | 613.42M | 698.68M | 897.14M |
IDEXX Laboratories, Inc.
NASDAQ:IDXX
Intrinsic Alpha fair value
Locked
Current Price
$698.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.